We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+5.9%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.17B
AUM Growth
-$91.9M
(-7.3%)
Cap. Flow
-$101M
Cap. Flow
% of AUM
-8.62%
Top 10 Holdings %
Top 10 Hldgs %
89.35%
Holding
33
New
1
Increased
11
Reduced
5
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$20.1M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$10.9M |
| 3 |
STAAR Surgical
STAA
|
+$8.98M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$7.27M |
| 5 |
Align Technology
ALGN
|
+$6.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$121M |
| 2 |
Gossamer Bio
GOSS
|
+$14.1M |
| 3 |
Vanda Pharmaceuticals
VNDA
|
+$10.5M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$8.49M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$5.32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.97% |
| 2 | Financials | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALIM
26
DELISTED
Alimera Sciences
ALIM
| $544K | 0.05% |
200,919
| – | – |
|
27
Tactile Systems Technology
TCMD
$555M
| $311K | 0.03% |
27,100
| – | – |
|
28
UroGen Pharma
URGN
$2.39B
| $217K | 0.02% |
24,500
| – | – |
|
|
29
Gossamer Bio
GOSS
$86.8M
| $81.9K | 0.01% |
37,750
-1,712,901
| -98% | -$14.1M |
|
30
Dianthus Therapeutics
DNTH
$6.29B
| – | – |
-27,019
| Closed | -$610K |
|
|
MRNS
31
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| – | – |
-31,330
| Closed | -$208K |
|
|
ABMD
32
DELISTED
Abiomed Inc
ABMD
| – | – |
-490,754
| Closed | -$121M |
|
|
CLVS
33
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-4,473,967
| Closed | -$5.32M |
|
Similar funds
AG
BL
PIM
ACA
PCM
HCM
ACM
DC
Palo Alto Investors's Q4 2022 Portfolio in Review
As of Q4 2022, Palo Alto Investors held 33 positions worth $1.17B, down 7.3% from $1.26B the previous quarter. Its ten largest holdings account for 89% of the portfolio.
Palo Alto Investors withdrew a net $101M in Q4 2022, closing 4 positions and reducing 5 holdings. Its most notable exit was Abiomed Inc, an estimated $121M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.
Against the trend, Palo Alto Investors opened a new position in Peak Bio, Inc. Common Stock worth $2.02M.
- Palo Alto Investors's largest Q4 2022 buy was Peak Bio, Inc. Common Stock: 497,528 shares worth $2.02M.
- Palo Alto Investors added most to Revance Therapeutics, Inc. in Q4 2022, an estimated $20.1M increase.
- Palo Alto Investors's biggest Q4 2022 reduction was Gossamer Bio, cutting an estimated $14.1M.
- Palo Alto Investors fully exited Abiomed Inc in Q4 2022, selling an estimated $121M.
- Palo Alto Investors's ten largest holdings make up 89% of its $1.17B portfolio in Q4 2022.
- Palo Alto Investors opened 1 new position and closed 4 in Q4 2022.
- Palo Alto Investors's portfolio value fell 7.3% quarter-over-quarter to $1.17B.
Based on Palo Alto Investors's 13F filing for Q4 2022, filed 14 Feb 2023.